KalVista Pharmaceuticals, Inc.
NASDAQ:KALVBiotechnology
+$0.00 today
- Market cap
- $1.44B
- Beta
- -0.11
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$2.74
Volume 4.26M
Average 3.47M
KALV Net Income
Bottom-line profit, the starting point for calculating cash from operations.
KalVista Pharmaceuticals, Inc.NASDAQ: KALV
Net Income · Q4 FY2026 · quarter ended Dec 2025
Net income of -$23.49M in Q4 FY2026
Q4 FY2026 net income was -$23.49M. Trailing-twelve-month net income was -$138.44M.
Context
- Net income amounted to 223.2% of revenue in FY2026.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$57.66M (-64.9%) for the fiscal year ending Dec 2026.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$23.49M— QoQ
- Last fiscal yearDec 2025
- -$164.29M— YoY
- LTMDec 2025
- -$138.44M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | -64.9% | — |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2026
- (164.29M) USD
- Year-over-year change
- +10.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2026 | 2025-12-31 | (164.29M) | +10.4% |
| FY2025 | 2025-04-30 | (183.44M) | -44.9% |
| FY2024 | 2024-04-30 | (126.64M) | -36.3% |
| FY2023 | 2023-04-30 | (92.91M) | -12.8% |
| FY2022 | 2022-04-30 | (82.34M) | — |
Net Income vs competitors
How KALV compares with its peers on the latest reported figures
- KALV's LTM Dec 2025 net income of $138.44M is the 8th largest of the 10 companies compared; the peer median is $160.9M.
- Net income amounts to 119.4% of revenue for KALV, versus a peer median of 292.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $364.23M | +879.7% | — | 121.5% | |
| LTM Mar 2026 | $218.8M | +7.2% | +24.8% | 344.6% | |
| LTM Mar 2026 | $193.96M | +30.3% | +41.6% | 391.2% | |
| LTM Mar 2026 | $185.15M | +43.6% | +15.7% | — | |
| LTM Mar 2026 | $180.4M | +252.1% | -9.4% | 324.8% | |
| LTM Mar 2026 | $160.9M | -8.8% | +9.2% | 182.3% | |
| LTM Mar 2026 | $151.18M | +37.1% | +27.8% | 260.9% | |
| LTM Dec 2025 | $138.44M | — | — | 119.4% | |
| LTM Mar 2026 | $136.99M | -8.6% | -3.2% | 173.0% | |
| LTM Mar 2026 | $81.36M | +148.9% | -73.6% | 822.4% | |
| Peer median (excluding KALV) | $160.9M | +37.1% | +12.5% | 292.9% | |
Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (82.34M) | (92.91M) | (126.64M) | (183.44M) | (164.29M) |
| Depreciation & Amortization | 743K | 718K | 816K | 941K | 1.45M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 9.92M | 21.92M | 12.29M | 0 |
| Change in Working Capital | (12.32M) | 7.41M | 15.17M | 15.04M | 954K |
| Accounts Receivables | (5.2M) | (2.32M) | 8.18M | (3.62M) | (7.4M) |
| Inventory | 0 | 0 | 0 | 0 | (3.43M) |
| Accounts Payables | 1.69M | 1.11M | 4.32M | (4.97M) | 4.19M |
| Other Working Capital | (8.81M) | 8.62M | 2.67M | 23.63M | 7.59M |
| Other Non-Cash Items | 15.78M | (407K) | (485K) | 2.27M | 80.26M |
| Operating Cash Flow | (78.13M) | (75.26M) | (89.23M) | (152.91M) | (81.62M) |
| Capital Expenditures | (931K) | (1.2M) | (443K) | (434K) | (1.71M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (136.92M) | (98.25M) | (189.23M) | (30.57M) | (84.78M) |
| Sales of Investments | 195.71M | 140.86M | 104.96M | 122.52M | 105.36M |
| Other Investing Activities | 0 | 0 | (401K) | 0 | 0 |
| Investing Cash Flow | 57.86M | 41.42M | (84.72M) | 91.02M | 18.68M |
| Debt Repayment | 0 | 0 | 0 | 98.04M | 160.72M |
| Common Stock Issued | 1.58M | 56.58M | 96.95M | 61.69M | 1.92M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 1.53M | 53.77M | 0 | 0 |
| Financing Cash Flow | 1.58M | 58.12M | 150.71M | 159.73M | 162.64M |
| Effect of Forex Changes | (1.17M) | 1.24M | (1.21M) | 1.98M | (1.98M) |
| Net Change in Cash | (19.86M) | 25.51M | (24.45M) | 99.83M | 97.73M |
| Free Cash Flow | (79.07M) | (76.46M) | (89.67M) | (153.34M) | (83.33M) |
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
Intrinsic Alpha fair value
Locked
Current Price
$27.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.